Home Newsfeeds Tilray Brands Says If Safe Act Passes, It Would Do “Nothing For Us”

News

Tilray Brands Says If Safe Act Passes, It Would Do “Nothing For Us”

– Reuters Citing Conf Call

byBenzinga Newsdesk

October 7, 2022

1 minute read

– Reuters Citing Conf Call

Wells Fargo Initiates Coverage On Xenon Pharmaceuticals with Overweight Rating, Announces Price Target of $50

By Benzinga Newsdesk

November 28, 8:21 AM

Wells Fargo analyst Mohit Bansal initiates coverage on Xenon Pharmaceuticals (NASDAQ:XENE) with a Overweight rating and announces Price Target of $50.

XENE

Diebold Nixdorf Shares Pop On Rating Upgrade: Key Takeaways

By Anusuya Lahiri

July 8, 2:08 PM

Wedbush analyst Matt Bryson upgraded Diebold Nixdorf Inc (NYSE: DBD) from Neutral to Outperform with a $5 price target. The projection reflected its strong…

DBD

Elevai Biosciences Highlights Preclinical Data Showing Potential Of In-Licensed Asset “EL-22” For The Treatment Of Obesity

By Benzinga Newsdesk

May 2, 8:39 AM

Preclinical results of EL-22 from a 2022 study demonstrated physiological (serum creatine kinase level), physical (body weight change), and functional (rotarod test) improvements in the dystrophic features of mdx mice, a

ELAB